About Sepax Technologies
Sepax Technologies is a Healthcare company based in Newark (United States) founded in 2002. Solutions for chromatographic biomolecular separation are developed and provided. Sepax Technologies has raised $109.24 million across 3 funding rounds from investors including Fosun, Gan & Lee Pharmaceutical and Sinopharm Capital. The company has 57 employees. Sepax Technologies offers products and services including Proteomix HIC Butyl, Zenix-C SEC, Monomix TM MC SEC Resins, and Proteomix RP-1000. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Chromatography. Its legal entity is SEPAX TECHNOLOGIES, INC. Its competitors include ChromaTan, Semba Biosciences and Sepragen; 3 of its 3 listed competitors have raised funding.
Company details
Sepax Technologies was founded in 2002 and is based in Newark, United States. Operations focus on the biotechnology sector, where products such as particle synthesis, surface modifications, LC column packing, and bulk media are produced for modalities including size exclusion, ion exchange, and reversed phase chromatography. Services encompass analytical chromatography, preparative purification, custom resins, and surface coatings, supporting biomolecular separation processes across various applications.
- Headquarters Newark, United States
- Employees 57
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website sepax-tech.com
- Social LinkedIn X Facebook
- Legal Name Sepax Technologies, Inc
- Total Equity Funding$109.24M (USD)
in 3 rounds
- Latest Funding Round$78.36M (USD), Series D
Nov 2021
- InvestorsFosun
& 7 more
- Employee Count57
Products & Services of Sepax Technologies
Sepax Technologies offers a comprehensive portfolio of products and services, including Proteomix HIC Butyl, Zenix-C SEC, Monomix TM MC SEC Resins, and Proteomix RP-1000.
Enables high-resolution hydrophobic interaction for biomolecules like mAbs.
Analyzes aggregates and fragments in antibody drug conjugates.
Provides stable SEC for broad pH ranges in protein purification.
Supports drug-to-antibody ratio analysis in ADCs.
Funding Insights of Sepax Technologies
Sepax Technologies has successfully raised a total of $109.24M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $78.36 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $109.24M
- Total Rounds 3
- Last Round Series D — $78.36M
- Investors Count 8
All 3 funding rounds of Sepax Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $78.36M | Series D | – | – | |
| Mar 2021 | $30.87M | Series C | – | China Life Insurance, Fosun | – |
| Jun 2018 | Series A | – | – | – |
8 investors in total: 8 institutional.
Investors in Sepax Technologies
Sepax Technologies has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Fosun, Gan & Lee Pharmaceutical and Sinopharm Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sinopharmcapital.com | ||||
| sherpahp.com | ||||
| hillhouseventures.tcc.mode | ||||
Acquisitions are targeted by CPE as a private equity firm. | cpe-fund.com | Beijing, China | ||
Private equity investments are managed from bases in China. | chinalifepe.com | Chaoyang, China | ||
Insulin analogs and medical devices are developed and commercialized. | 1988 | ganlee.com | Beijing, China | |
| kexingholdings.tcc.mode | ||||
Diversified investment, asset management, and insurance services are offered globally. | 1992 | fosun.com | Shanghai, China |
Investor details for Sepax Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sepax Technologies
8 people are tracked at Sepax Technologies (3 in leadership, 5 in team); the tracked headcount is 57.
| Name | Role | Group |
|---|---|---|
Xueying Huang | President | Leadership |
Tingzhou Wu | VP Of Sales And Marketing | Leadership |
Kathleen Falls | VP Of Sales, Marketing, And Tech Support | Leadership |
Sam Tarantino | Field Sales Manager | Team |
Anthony Sokol | Business Development Manager | Team |
Chen Fan (Aaron) | Senior Manager Of Corporate Services | Team |
Jessica Chapple | Sales And Marketing Specialist | Team |
海松 郭 | Bd项目经理 | Team |
Complete people profiles for Sepax Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sepax Technologies
3 dated milestones of Sepax Technologies across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Sepax Technologies is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $78.4M.
Competitors of Sepax Technologies
Sepax Technologies has 3 listed competitors in our database, 3 of them funded. They include ChromaTan, Semba Biosciences and Sepragen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| chromatan.com | 2009 | State College, United States | $5.32M | Continuous countercurrent tangential chromatography separation technology is developed. | ||
| sembabio.com | 2005 | Madison, United States | $5.85M | Provider of systems for molecular separation based on simulated moving bed chromatography (SMBC) | ||
| sepragen.com | 1987 | Hayward, United States | $5M | 19 | Biomolecular separation technologies are enabled for bioprocessing applications. |
Detailed competitors of Sepax Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sepax Technologies
The website of Sepax Technologies (sepax-tech.com) receives about 2K visits a month.
- Monthly visits2K
▲ 3.4% vs previous month
Websites whose visitors overlap most with Sepax Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bio-connect.nl | 100% | 27.1K | #1,078,126 | View details | |
| raindancetech.com | 94% | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Sepax Technologies (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sepax Technologies
Complete news archive for Sepax Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sepax Technologies
Sepax Technologies was founded in 2002 and raised its 1st funding round 16 years after it was founded.
Sepax Technologies is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
Sepax Technologies is a funded company, having raised a total of $109.24M across 3 funding rounds to date.
Sepax Technologies has 57 employees.
Sepax Technologies was founded in 2002 and is based in Newark, United States. Operations focus on the biotechnology sector, where products such as particle synthesis, surface modifications, LC column packing, and bulk media are produced for modalities including size exclusion, ion exchange, and reversed phase chromatography. Services encompass analytical chromatography, preparative purification, custom resins, and surface coatings, supporting biomolecular separation processes across various applications.
Sepax Technologies's top competitors include ChromaTan, Sepragen and Semba Biosciences.
Sepax Technologies offers Proteomix HIC Butyl, Zenix-C SEC, Monomix TM MC SEC Resins, and Proteomix RP-1000.
Sepax Technologies has 8 investors. Key investors include Fosun, Gan & Lee Pharmaceutical, Sinopharm Capital, Sherpa Healthcare Partners, and Hillhouse Ventures.
Sepax Technologies operates through Sepax Technologies, Inc.